glp 1 in heart failure Effects of Glucagon-Like Peptide Receptor Agonist Initiation Patients With With Reduced Ejection Fraction and Implantable Cardiac Devices Glucagon-like peptide 1 receptor agonists:

Food and Drug Administration (FDA) and the Central Drugs Standard Control Organisation (CDSCO) in India, have approved GLP-1 RAs based on their safety and efficacy 3 , 6

The most common side effects reported by patients are mild to moderate gastrointestinal symptoms, such as nausea, vomiting, diarrhea, and constipation

The pen's internal mechanism automatically accounts for this concentration, so patients simply select their prescribed dose in milligrams on the dose counter

Poorly absorbed, ferment in the gut, effects amplified by delayed gastric emptying

To avoid or minimize these effects, the medications are started at a low dose and then ramped up slowly over a few months

Customizable for Your Needs: Not dealing with nausea